Use of Botulinum Toxin in Overactive Bladder - Diabetic Neurogenic Bladder Treatment

Use of Botulinum Toxin in Overactive Bladder
European Urology Supplements
Volume 5, Issue 11, July 2006, Pages 667-669

Copy and paste the URL into a browser to view this article.
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6X11-4K5JBTS-1&_user=10&_coverDate=07%2F31%2F2006&_rdoc=2&_fmt=high&_orig=browse&_srch=doc-info(%23toc%237229%232006%23999949988%23626955%23FLA%23display%23Volume)&_cdi=7229&_sort=d&_docanchor=&_ct=6&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=8a37c221c240b2b038195e528a7afe8a

Jacques Corcos a, and Brigitte Schurch b
aDepartment of Urology, Jewish General Hospital, McGill University, Montreal, Canada
bSpinal Cord Injury Centre, University Hospital Balgrist, Zurich, Switzerland
Available online 12 June 2006.

Abstract
Overactive bladder (OAB) has significant morbidity in the general population, and effective management is important both to minimise the impact on the patient's quality of life and to prevent the development of chronic health problems. Accumulating data from clinical studies and a growing body of clinical experience suggest that botulinum toxin A (BoNTA) may be an appropriate treatment, particularly in patients in whom the efficacy or tolerability of anticholinergics is in doubt. This supplement supplies a rationale for the use of BoNTA in OAB, discussing its mechanism of action and presenting data on its efficacy and safety in patients with neurogenic detrusor overactivity (NDO) and idiopathic detrusor overactivity. It also considers NDO in the context of other disorders from which these patients may suffer.

Keywords: Botulinum toxin; Idiopathic detrusor overactivity; Neurogenic detrusor overactivity; Overactive bladder; Urinary incontinence